Epithelial-mesenchymal transition (EMT) and its reverse, mesenchymal-epithelial transition (MET), are developmental programs that have been shown to play critical roles in promoting metastasis and invasion as well as contribute to drug resistance in carcinoma. ATCC has employed CRISPR/Cas9 gene editing to develop new reporter lines designed to enable the real-time monitoring of the changing status of cells from epithelial to mesenchymal.
- CRISPR/Cas9 gene-edited vimentin-RFP fusion protein
- Strong RFP signal upon vimentin induction
- Physiological E-cadherin expression in absence of EMT
- Lung or colon models currently available
Increased invasive capacity following EMT
TGFβ1-responsive (lung model)
Sensitive to A83-01 and PP1 inhibition (lung model)
miR-200 family inhibitor-responsive (colon model)
Scientific Paper: Live-cell imaging and analysis reveal cell phenotypic transition dynamics inherently missing in snapshot data
Recent advances in single-cell techniques allow for the study of how cells convert from epithelial to mesenchymal phenotypes.
This research paper describes a live-cell imaging platform that tracks cellular status change through combining endogenous fluorescent labeling and live-cell imaging of high-dimensional cell morphological and texture features.
With this platform and A549 VIM-RFP epithelial-to-mesenchymal transition (EMT) reporter cell line (ATCC® CCL-185EMT™), live-cell imaging of EMT is possible. Read this recent Science Advances article to appreciate the phenotypic transitions captured from multiplex live-cell imaging.
Fluorescence-labeled EMT Reporter
Validation of A549-Vim-RFP
Upon EMT induction, the EMT reporter cell line undergoes morphological changes from epithelial to mesenchymal and demonstrates increased expression of Vim-RFP. Learn more about how ATCC created and validated these advanced EMT models from the flyer.